55
views
0
recommends
+1 Recommend
3 collections
    0
    shares

      Call for Papers: Cancer Biology and Therapy

      Submit here by August 31, 2025

      About Cytogenetic and Genome Research: 1.7 Impact Factor I 3.1 CiteScore I 0.385 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          During the COVID-19 pandemic, Lombardy (Northern Italy) Regional Health Council created hubs for cancer care, meant to be SARS-CoV-2-free pathways for cancer patients. The workflow of breast cancer (BC) radiotherapy (RT) in one of the hubs is presented here.

          Methods

          Candidates to adjuvant RT during the pandemic peak of March-April 2020 were compared to those treated in the same period of 2019, and patient volume, deferral rate, and type of RT were analyzed. Statistics were calculated with χ<sup>2</sup> or Fisher exact tests for categorical variables, and the Wilcoxon rank test for continuous variables.

          Results

          In March-April 2020 the BC patient volume increased by 28% compared to the same period in 2019 (scheduled patients: 175 vs. 137) and amid travel restrictions it was kept high (treated patients: 136 vs. 133), mainly due to an influx from across Lombardy. RT schemes basically did not change, being already centered on hypofractionation. The increase of median time (67 vs. 74.5 days in 2019 and 2020, respectively) to the commencement of RT for low-risk patients was clinically negligible yet statistically significant ( p = 0.03), and in line with the pertinent recommendations. No significant difference was found in the time interval between treatments and RT for high-risk patients. Concomitant chemoradiotherapy was avoided throughout the pandemic peak. Twenty-one women (13.6%) delayed either computed tomography simulation or RT commencement mainly because of COVID-19-related concerns and mobility restrictions.

          Conclusion

          The workload for BC was high during the pandemic peak. Hubs allowed the continuation of oncologic treatments, while mitigating the strain on frontline COVID-19 hospitals.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: found

          Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

            • Record: found
            • Abstract: found
            • Article: not found

            ESMO-Magnitude of Clinical Benefit Scale version 1.1.

            The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.0 (v1.0) was published in May 2015 and was the first version of a validated and reproducible tool to assess the magnitude of clinical benefit from new cancer therapies. The ESMO-MCBS was designed to be a dynamic tool with planned revisions and updates based upon recognition of expanding needs and shortcomings identified since the last review.
              • Record: found
              • Abstract: found
              • Article: not found

              Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement.

              To update the accelerated partial breast irradiation Consensus Statement published in 2009 and provide guidance on use of intraoperative radiation therapy (IORT) for partial breast irradiation in early-stage breast cancer, based on published evidence complemented by expert opinion.

                Author and article information

                Journal
                Breast Care (Basel)
                Breast Care (Basel)
                BRC
                Breast Care
                S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com )
                1661-3791
                1661-3805
                16 December 2020
                : 5
                : 1-7
                Affiliations
                [1] aDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
                [2] bDivision of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
                [3] cDivision of Breast Surgery, IEO, European Institute of Oncology, IRCCS, Milan, Italy
                [4] dDivision of Data Management, IEO, European Institute of Oncology, IRCCS, Milan, Italy
                [5] eDepartment of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
                [6] fDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
                [7] gUnit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
                [8] hMedical Administration, CMO, IEO, European Institute of Oncology, IRCCS, Milan, Italy
                [9] iScientific Direction, IEO, European Institute of Oncology, IRCCS, Milan, Italy
                Author notes
                *Damaris Patricia Rojas, Division of Radiation Oncology, European Institute of Oncology, IEO, IRCCS, Via Ripamonti 435, IT–20141 Milan (Italy), damarispatricia.rojas@ 123456ieo.it
                Article
                brc-0005-0001
                10.1159/000513227
                7801963
                34191930
                f9fedc73-3060-45d6-8d2c-03b24e4b4189
                Copyright © 2020 by S. Karger AG, Basel

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                History
                : 1 September 2020
                : 11 November 2020
                Page count
                Figures: 2, Tables: 2, References: 25, Pages: 7
                Categories
                Research Article

                covid-19,pandemic,breast cancer,oncologic care,hub
                covid-19, pandemic, breast cancer, oncologic care, hub

                Comments

                Comment on this article

                Related Documents Log